|
|
|
|
|
|
|
|
|
|
|
|
|
|
Daniel
J. O'Connell, Managing Partner,
djo@neuroventures.com
Dan
is one of the founders and serves as managing partner of NeuroVentures, a
specialty venture firm, established in 2001 to invest in emerging
biopharmaceutical and medical technology companies
developing better treatments for Central Nervous System diseases.
Dan
represents NeuroVentures on the boards of Setagon Inc. and Acumen
Pharmaceuticals, Inc. In
addition, he serves as a board observer at BrainCells Inc., Concentric Medical Inc.,
and previously Cyberkinetics
Neurotechnology Systems Inc.
Dan’s experience with neuro-related technology companies includes
co-founding MedSpecialists, Inc., a venture-backed clinical applications
provider acquired by ProVation
Medical Inc., and Surgical Solutions, LLC, a company which developed
and marketed neurosurgical products licensed from leading research
institutions. Dan is a
member of the Business Advisory Boards of the Epilepsy Therapy Development Project
and the Alzheimer's Drug Discovery
Foundation. He serves on the Board of the Neurotechnology Industry
Organization.
Prior to attending
business school, Dan worked in investment banking at Advest, Inc. He holds a B.A. from Brown
University and M.B.A. from the University of Virginia.
Back
to top
|
|
|
|
|
Mark A. Cochran, Ph.D., Founding Partner
Mark served as Managing Director of NeuroVentures from its inception in
late 2000 through April 2006. He remains active with several NeuroVentures
portfolio companies and continues to serve as an advisor to the firm.
Currently, he is Chief Executive Officer and Executive Director of the Blanchette Rockefeller Neurological Research
Institute (BRNI) in Morgantown, WV. BRNI is a non-profit research
institute dedicated to the study of human memory. Its primary mission is
to accelerate neurological discoveries from the lab, including diagnostic
tools and treatments, directly to patients who are suffering from
neurological diseases such as Alzheimer's.
Previously,
Dr. Cochran worked with MDS Capital Corporation, a Toronto-based
healthcare venture capital group where he was responsible for MDS' San
Francisco venture business and several MDS invested companies. His prior
experience in the pharmaceutical and biotechnology industry includes
Bayer Pharmaceuticals, most recently as vice president of business
development, biotechnology, in Berkeley, California. Other positions held
during his tenure at Bayer included project director of Recombinant
Factor VIII, and head of molecular biology and biochemistry in Wuppertal,
Germany. Before joining Bayer, Dr. Cochran co-founded MicroGeneSys, Inc.,
a Connecticut-based vaccine company. He is listed as the author on 22 scientific
papers, 66 abstracts and six patents.
Dr. Cochran received
his Ph.D. from the Department of Molecular Biology and Immunology at
Queen's University in Kingston,
Canada. He
holds a Masters from the University
of Guelph and a B.Sc. from the University
of Toronto. Dr.
Cochran performed post-doctoral research at the National Institutes of
Health in Bethesda, MD.
Back to top
|
|
|
|
|
|
|
|
|
|
Frank A.
Bonsal, Jr.,
Founding Partner, New Enterprise Associates, Inc.
John W.
Glynn, Jr.,
Founder, Managing General Partner, Glynn Ventures, Inc.
James B.
Murray, Jr.,
Founder, Managing Director, Court Square Ventures, Founder and Former
Chairman Columbia Capital Corporation, Inc.
The Investment
Committee must approve by majority vote all of the Fund’s potential
investments and dispositions of material investments. The Investment
Committee also advises on matters such as investment strategy, portfolio
valuation, potential conflicts of interest and other Fund issues.
Back to top
|
|
|
|
|
NeuroVentures
has assembled a group of highly distinguished neuroscientists and
clinicians from leading research institutions in the U.S.
to serve as advisors to the Fund. The initial members of this Advisory
Board are:
Floyd E.
Bloom, M.D.,
Chairman of the Department of Neuropharmacology at The Scripps Research
Institute in La Jolla, and Chairman and
Chief Executive Officer of Neurome Inc.
Zach W.
Hall, Ph.D.,
Senior Associate Dean for Research, Keck School of Medicine, University
of Southern California; former President and CEO, EnVivo Pharmaceuticals,
Inc.; Former Vice Chancellor,
University of California, San Francisco; Former Director, National
Institutes of Health, National Institute of Neurological Disease and
Stroke
Neal F.
Kassell, M.D.,
Crutchfield Professor of Neurosurgery, Co-Chairman of Neurological
Surgery, University
of Virginia Health
System
William
C. Mobley, M.D., Ph.D., Professor and Chair of the Department of
Neurology and Neurological Sciences at Stanford
University, California
Donald L.
Price, M.D.,
Professor of Pathology, Neurology, and Neuroscience at The Johns Hopkins
University School of Medicine; Director of the Division of Neuropathology
at The Johns Hopkins Hospital; and Director of the Alzheimer’s Disease
Research Center at The Johns Hopkins University School of Medicine
John M.
Tew, Jr., M.D.,
Neurosurgeon with the Mayfield Clinic, Cincinnati, Ohio; Chair of the
Department of Neurosurgery at the University of Cincinnati College of
Medicine; and Medical Director of The Neuroscience Institute at The
University Hospital
Justin A.
Zivin, M.D., Ph.D., Professor, Neurosciences, University
of California, San
Diego
This
principal group of physician-scientists is further augmented by other contacts
and relationships at leading research centers worldwide.
Back to top
|
|
|
|
Terrence D.
Daniels,
Founder, Managing General Partner, Quad-C Funds, Inc.
Eugene V.
Fife,
Founding Principal, Vawter Capital, LLC, Former Chairman, Goldman Sachs
International
Philip
Goelet, PhD.,
Managing Member, Red Abbey LLC
Hans von
Celsing,
Former EVP, Elekta AB.
Truman T.
Semans,
Vice Chairman, Brown Investment Advisory & Trust Company
Back to top
|
|
|
